 |
3,4-Diaminopyridine phosphate |
|---|---|
| Trade Name | |
| Orphan Indication | Lambert-Eaton Myasthenic Syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2009-11-12 00:00:00 |
| Sponsor | Catalyst Pharmaceutical Partners, Inc.;355 Alhambra Circle, Suite 1500;Coral Gables, FL, 33134 |
Related Access Program
David Lacomis – Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. – Lambert-Eaton Myasthenic Syndrome
Ricardo Maselli – Lambert-Eaton Myasthenic Syndrome
Vern C. Juel, M.D. – Lambert-Eaton Myasthenic Syndrome
Tessa L Marburger – Lambert-Eaton Myasthenic Syndrome
University of Colorado, Denver – Lambert-Eaton Myasthenic Syndrome
University of Pittsburgh – Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceutical Partners, Inc – Lambert-Eaton Myasthenic Syndrome
The Cleveland Clinic – Lambert-Eaton Myasthenic Syndrome